Phase 2 N=19 Neoadjuvant Ipilimumab in Prostate Cancer
Prostate Cancer
Primary: Immunologic Response: Number of Participants With Immune Response — 12; 7; 9 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=242 Repeat Injection of Cingal® for Osteoarthritis of the Knee
Osteoarthritis of the Knee
Primary: Number of Treatment-Emergent Adverse Events: Cingal 13-02 vs. Cingal 13-01 — 73 Adverse events — p=0.3108
Phase 2 N=183 Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye Disease
Dry Eye Disease
Primary: Mean Change From Baseline in Lacrimation Assessed by Schirmer's Test — 3.02; 2.15; 2.35; 1.35 mm
Phase 4 N=80 Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of Adverse Events (AEs) — 55.0; 70.0; 57.9 Percentage of participant with AEs
N/A N=56,332 Disparities in National Kidney Allocation Policy
Kidney Disorders
Primary: Proportion of Incident Patients Waitlisted — 1.39; 1.33; 1.25; 1.30 adjusted mean proportion of patients
N/A N=227 A Clinical Evaluation of the Durata or Optisure High Voltage Leads and Ellipse VR ICD Undergoing MRI, an IDE Study
Implantable Defibrillator User
Primary: Number of Participants With MRI Scan Related Complications — 0 Participants
Phase 4 N=211 Misoprostol 400 µg Versus 200 µg for Cervical Ripening in 1st Trimester Miscarriage
Miscarriage in First Trimester
Primary: Number of Participants Who Required Cervix Dilation at Initiation of the Manual Vacuum Aspiration — 4; 16; 102; 89 Participants — p=0.025
Phase 4 N=103 The Effect of Different Sedation Regimes on Cognitive Function in Lower Gastrointestinal System Endoscopy
Gastrointestinal Dysfunction · Alteration of Cognitive Function
Primary: Change in Cognitive Function — 47.5; 40.4; 44.7; 37.8 units on a scale — p=0.001
Phase 3 N=239 Bioequivalence Study for Benzyl Alcohol Lotion 5%.
Head Lice
Primary: Number of Participants With Infestation Successfully Eliminated by Active Treatment. — 59; 57; 6 Participants
Phase 2 N=415 Evaluation of BOL-303242-X Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery
Cataract · Inflammation
Primary: Percentage of Participants With Complete Resolution of Anterior Chamber (AC) Cells. — 35; 19; 15; 47 Participants
Phase 3 N=369 Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Cataract · Inflammation · Surgery
Primary: Percentage of Participants With Complete Resolution of Anterior Chamber (AC) Cells — 49; 15 Participants
N/A N=68 Effects of Lentinula Edodes Bars on Dyslipidemia and Oxidative Stress in Cholesterol Individuals: Randomized Study
Dyslipidemias
Primary: Total Cholesterol Levels — 222.8; 228.2; 226.7; 229.6 mg/dL — p=0.59
Phase 2 N=885 Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine
Migraine · Acute Treatment of Migraine
Primary: Number of Pain Free Participants (Pain Freedom) at 2 Hours Post-dose — 14; 12; 27; 28 Participants
N/A N=27 A Randomized Controlled Trial Investigating if Antibiotic Use in the First 48 Hours of Life Adversely Impacts the Preterm Infant Microbiome
Premature Birth of Newborn · Enterocolitis, Necrotizing
Primary: Richness of the Preterm Infant Microbiome — 12.8; 11 16S rRNA gene amplicon sequence variants
Phase 3 N=311 Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery
Cataract
Primary: Percentage of Participants With Complete Resolution of Anterior Chamber (AC) Cells. — 32; 12 Participants